Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-16

Clinical Trial Update: Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating natalizumab for Crohn's disease has completed, reporting on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED